ERN1 and Miyoshi myopathy: Previous publications showed that the inhibition or disruption of the IRE1a-XBP1s axis in MM cells can reduce tumor progression [17,18,19] and can synergize with MM-specific drugs such as bortezomib and lenalidomide [17,20].